Moreover, in individuals treated with adjuvant chemotherapy, CDX2-negative colon cancers in stage II were found to have a significantly increased five-year DFS (91%) in comparison with those who did not undergo adjuvant chemotherapy (56%) [220]. The gene discussed is CDX2; the disease is malignant colon neoplasm.